F3 is a social application that enables users to pose questions and share answers, with all content automatically expiring after 72 hours. This ephemeral format mitigates concerns about privacy and digital footprint by ensuring that interactions are temporary and less traceable.

Giiant Pharma develops gut-restricted, orally delivered small molecule therapeutics specifically targeting inflammatory bowel diseases (IBD) using its Gastrointestinal-Induced Anti-inflammatory technology, which utilizes gut microbiota to activate drugs in the lower GI tract. This approach aims to enhance drug tolerability and minimize systemic side effects, addressing the significant impact of treatment-associated adverse effects on patient quality of life and adherence.

Inversago Pharma develops peripherally acting CB1 receptor blockers to treat metabolic conditions such as diabetic kidney disease, obesity, and non-alcoholic steatohepatitis. Their lead program, INV-202, is currently in Phase 2 trials, targeting the complications associated with diabetes and obesity.

Provides a security platform that enables regulated enterprises to safely integrate and govern generative AI across all workflows, including web applications and desktop environments. It ensures complete data security, granular access controls, and real-time observability, allowing organizations to leverage AI tools without compromising compliance or privacy.

RA UNLIMITED harnesses solar photovoltaic technology to generate clean and affordable electricity for homes, businesses, and communities in the Philippines. The company addresses the reliance on fossil fuels by providing sustainable energy solutions that create jobs and enhance the quality of life for Filipinos.

The startup develops anti-SEMA 3A therapies targeting ocular diseases such as diabetic macular edema and wet age-related macular degeneration. By providing protein inhibitors, the company enables physicians to treat these retinopathies and potentially address related neurodegenerative conditions.